Search results
Results from the WOW.Com Content Network
This is a list of investigational autism and pervasive developmental disorder drugs, or drugs that are currently under development for clinical use in the treatment of autistic spectrum disorders and/or other pervasive developmental disorders but are not yet approved.
The use of technology has begun to be implemented in ABA therapy for the treatment of autism. [49] Robots, gamification, image processing, story boards, augmented reality, and web systems have been shown to be useful in the treatment of autism. [49] These technologies are used to teach children with autism skill acquisition. [49]
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
Child psychopathology refers to the scientific study of mental disorders in children and adolescents. Oppositional defiant disorder, attention-deficit hyperactivity disorder, and autism spectrum disorder are examples of psychopathology that are typically first diagnosed during childhood. [1]
Developmental disorders are present from early life onward. Most improve as the child grows older, but some entail impairments that continue throughout life. These disorders differ from Pervasive developmental disorders (PPD), which uniquely describe a group of five developmental diagnoses, one of which is autism spectrum disorders (ASD ...
Pages in category "Treatment of autism" ... and pervasive developmental disorder drugs; K. KM-391 ... of Autistic and Related Communication Handicapped Children; V.
The first three of these disorders are commonly called the autism spectrum disorders; the last two disorders are much rarer, and are sometimes placed in the autism spectrum and sometimes not. [2] [3] In May 2013, the Diagnostic and Statistical Manual–5th Edition (DSM-5) was released, updating the classification for pervasive developmental ...
Psilocybin (PSY-0.1, PSY-0.2, PSY-0.3, PSY-0.4/0.5, PSY-0.6) – non-selective serotonin receptor agonist and psychedelic hallucinogen – substance-related disorders, neurological disorders, opioid-related disorders, psychiatric disorders, traumatic brain injury, cancer, anxiety disorders, bipolar disorders, depressive disorders, eating ...